UniQure’s Huntington’s gene therapy AMT-130 continues to show disease progression slowing four years after implantation, but the company’s benefit magnitude appears to have declined versus earlier analyses. The new longer-term data adds uncertainty for durability as regulators review the marketing application. The update arrives as investors and clinicians look for sustained functional benefit, not only slowed biomarker progression. The reported results also include changes in statistical strength and endpoint interpretability compared with prior checkpoints. For biotech developers, Huntington’s durability signal is a template risk: regulators often scrutinize the difference between initial slowing and long-lasting clinical impact. The company’s next steps will hinge on whether the dataset can preserve a convincing clinical narrative for approval.